Peng Lei1, Scott Ayton2, Ashley I Bush3. 1. Department of Neurology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, P.R. China; Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia. Electronic address: peng.lei@scu.edu.cn. 2. Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia. 3. Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia. Electronic address: ashley.bush@florey.edu.au.
Abstract
Treatments for Alzheimer's disease (AD) directed against the prominent amyloid plaque neuropathology are yet to be proved effective despite many phase 3 clinical trials. There are several other neurochemical abnormalities that occur in the AD brain that warrant renewed emphasis as potential therapeutic targets for this disease. Among those are the elementomic signatures of iron, copper, zinc, and selenium. Here, we review these essential elements of AD for their broad potential to contribute to Alzheimer's pathophysiology, and we also highlight more recent attempts to translate these findings into therapeutics. A reinspection of large bodies of discovery in the AD field, such as this, may inspire new thinking about pathogenesis and therapeutic targets.
Treatments for Alzheimer's disease (n class="Disease">AD) directed against the prominent amyloid plaque neuropathology are yet to be proved effective despite many phase 3 clinical trials. There are several other neurochemical abnormalities that occur in the AD brain that warrant renewed emphasis as potential therapeutic targets for this disease. Among those are the elementomic signatures of iron, copper, zinc, and selenium. Here, we review these essential elements of AD for their broad potential to contribute to Alzheimer's pathophysiology, and we also highlight more recent attempts to translate these findings into therapeutics. A reinspection of large bodies of discovery in the AD field, such as this, may inspire new thinking about pathogenesis and therapeutic targets.
Authors: Shashank Masaldan; Ashley I Bush; David Devos; Anne Sophie Rolland; Caroline Moreau Journal: Free Radic Biol Med Date: 2018-09-25 Impact factor: 7.376
Authors: Su Ling Leong; Tessa R Young; Kevin J Barnham; Anthony G Wedd; Mark G Hinds; Zhiguang Xiao; Roberto Cappai Journal: Metallomics Date: 2014-01 Impact factor: 4.526
Authors: Peng Lei; Scott Ayton; Steve Moon; Qihao Zhang; Irene Volitakis; David I Finkelstein; Ashley I Bush Journal: Mol Neurodegener Date: 2014-08-14 Impact factor: 14.195
Authors: Bruce X Wong; Andrew Tsatsanis; Linh Q Lim; Paul A Adlard; Ashley I Bush; James A Duce Journal: PLoS One Date: 2014-12-02 Impact factor: 3.240